This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

In vivo assessment of amyloid-β deposition in nondemented very elderly subjects


Mathis, Chester A., Kuller, Lewis H., Klunk, William E., Snitz, Beth E., Price, Julie C., Weissfeld, Lisa A., Rosario, Bedda L., Lopresti, Brian J., Saxton, Judith A., Aizenstein, Howard J., McDade, Eric M., Kamboh, M. Ilyas, DeKosky, Steven T., Lopez, Oscar L.


Annals Of Neurology, Volume: 73, No.: 6, Pages.: 751-761

Year of Publication



Objective: This study examined amyloid-β (Aβ) deposition in 190 nondemented subjects aged ≥82 years to determine the proportion of Aβ-positive scans and associations with cognition, apolipoprotein E (APOE) status, brain volume, and Ginkgo biloba (Gb) treatment.; Methods: Subjects who agreed to participate had a brain magnetic resonance imaging and positron emission tomography scan with (11) C-labeled Pittsburgh compound B (PiB) following completion of a Gb treatment clinical trial. The youngest subject in this imaging study was 82 years, and the mean age of the subjects was 85.5 years at the time of the scans; 152 (80%) were cognitively normal, and 38 (20%) were diagnosed with mild cognitive impairment (MCI) at the time of the PiB study.; Results: A high proportion of the cognitively normal subjects (51%) and MCI subjects (68%) were PiB-positive. The APOE*4 allele was more prevalent in PiB-positive than in PiB-negative subjects (30% vs 6%). Measures of memory, language, and attentional functions were worse in PiB-positive than in PiB-negative subjects, when both normal and MCI cases were analyzed together; however, no significant associations were observed within either normal or MCI subject groups alone. There was no relationship between Gb treatment and Aβ deposition as determined by PiB.; Interpretation: The data revealed a 55% prevalence of PiB positivity in nondemented subjects age >80 years and 85% PiB positivity in the APOE*4 nondemented elderly subjects. The findings also showed that long-term exposure to Gb did not affect the prevalence of cerebral Aβ deposition.; © 2013 American Neurological Association.

Bibtex Citation

@article{Mathis_2013, doi = {10.1002/ana.23797}, url = {}, year = 2013, month = {apr}, publisher = {Wiley-Blackwell}, volume = {73}, number = {6}, pages = {751--761}, author = {Chester A. Mathis and Lewis H. Kuller and William E. Klunk and Beth E. Snitz and Julie C. Price and Lisa A. Weissfeld and Bedda L. Rosario and Brian J. Lopresti and Judith A. Saxton and Howard J. Aizenstein and Eric M. McDade and M. Ilyas Kamboh and Steven T. DeKosky and Oscar L. Lopez}, title = {In vivo assessment of amyloid-$upbeta$ deposition in nondemented very elderly subjects}, journal = {Annals of Neurology} }


adult, aged, aged, 80 and over, aniline compounds, biloba, brain, deposition, diagnosis, diagnostic use, double-blind method, epidemiology, female, ginkgo, humans, male, metabolism, methods, middle aged, mild cognitive impairment, pathology, prevalence, thiazoles

Countries of Study


Types of Dementia

Dementia (general / unspecified)

Types of Study

Randomised Controlled Trial

Type of Outcomes


Type of Interventions

Diagnostic Target Identification, Pharmaceutical Interventions

Risk Factor Modifications

At risk population